← board
PMCB
distress 4/10 · elevated risk$0.610%today-50% from 52w high
Revenue
pre-revenue
Liquidity
$21M
Runway
6.9 yrs
Shares 1y
+58%
Price & events
-32.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.0%
1D
-7.6%
1W
-21.4%
1M
-18.7%
3M
-35.0%
6M
-36.5%
1Y
-69.4%
2Y
-94.5%
5Y
-94.8%
All
Overview
- Market Cap
- $6.55M
- Volume
- 22.45K
- 52 Week Range
- $0.61 – $1.22
- Total Shares
- 10.74M
- Float Shares
- 9.96M
- Short %
- 3.22%
- % Held by Insiders
- 5.74%
- % Held by Institutions
- 9.01%
- RVOL
- 0.23x
- Beta
- 0.52
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-09-02partnershipPharmaCyte entered into securities purchase agreement to invest $3M in TNF PharmaceuticalsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.